At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
ACZ885 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary Sarcoidosis
In Brief
A Phase 2 clinical trial evaluating ACZ885 and Placebo for Pulmonary Sarcoidosis. Completed, enrolled 40 participants across 8 sites in 3 countries.
Detailed Summary
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Sarcoidosis
CountriesGermany, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartDec 2016
Primary CompletionMar 2019
TodayJul 2026
First PostedSep 2, 2016
Enrollment StartDec 19, 2016
Primary CompletionMar 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.8 years ago
Interventions
ACZ885drug
ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
Placebodrug
Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.